New antiviral shot could boost flu protection when given with vaccine
NCT ID NCT07300085
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This early-stage trial is testing whether a new long-acting antiviral medicine called CD388 can be safely given at the same time as the high-dose flu vaccine. About 100 healthy adults aged 18 to 49 will receive either the vaccine plus CD388 or the vaccine plus a placebo. Researchers will check if CD388 interferes with the body's immune response to the vaccine and monitor for any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
California Clinical Trials Medical Group (CCTMG) managed by Parexel
Glendale, California, 91206, United States
-
Parexel International - EPCU Baltimore
Baltimore, Maryland, 21225, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fluzone High-Dose influenza vaccine and CD388 (a long-acting antiviral)
What this could lead to
If successful, this could show that combining a long-acting antiviral with the flu vaccine is safe and doesn't reduce vaccine effectiveness, potentially offering better flu prevention.
What could go wrong
This is a very early (phase 1) and small trial (100 healthy adults), so results may not apply to older or sicker people. The main goal is safety and immune response, not proof of preventing flu.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.